Related Experiment Video

Updated: Sep 22, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies

Blanca Scheijen1

  • 1Department of Pathology, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, GA 6525, Nijmegen, the Netherlands.

Cancer Drug Resistance (Alhambra, Calif.)
|May 18, 2022
PubMed

Insights

Glucocorticoids (GCs) are vital for lymphoid tumors, but resistance is common. This review details molecular mechanisms like altered glucocorticoid receptor (GR) expression and chromatin changes driving GC resistance in these cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glucocorticoids (GCs) are foundational in treating lymphoid malignancies.
  • Acquired resistance to GC therapy significantly impacts patient outcomes.
  • Understanding resistance mechanisms is crucial for improving treatment efficacy.

Purpose of the Study:

  • To review the molecular mechanisms underlying glucocorticoid resistance in lymphoid tumors.
  • To highlight the interplay between resistance pathways and genetic alterations in relapsed disease.

Main Methods:

  • Literature review of studies on glucocorticoid resistance in lymphoid malignancies.
  • Analysis of molecular mechanisms including receptor expression, signaling pathways, and chromatin accessibility.

Main Results:

  • Key mechanisms include suppressed glucocorticoid receptor (GR) expression.
  • Dysregulated cell signaling pathways modulate GR function.
  • Altered transcriptional co-regulation and chromatin accessibility contribute to resistance.
  • These mechanisms are often linked to genetic alterations in relapsed lymphoid cancers.

Conclusions:

  • Multiple interconnected molecular mechanisms contribute to GC resistance in lymphoid tumors.
  • Targeting these pathways may offer strategies to overcome resistance.
  • Further research is needed to translate these findings into clinical practice.
Keywords:
Glucocorticoid receptoracute lymphoblastic leukemiamultiple myelomanon-Hodgkin lymphomatherapy resistance

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
281
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
74.5K